CDK4/6 inhibition in cancer: the cell cycle splicing connection

por Sheppard, Karen E., AbuHammad, Shatha
Publicado 2019

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

por Lelliott, Emily J., Sheppard, Karen E., McArthur, Grant A.
Publicado 2022

AKT-independent PI3-K signaling in cancer – emerging role for SGK3

por Bruhn, Maressa A, Pearson, Richard B, Hannan, Ross D, Sheppard, Karen E
Publicado 2013

Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma

por Lelliott, Emily J., McArthur, Grant A., Oliaro, Jane, Sheppard, Karen E.
Publicado 2021

Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies

por Alkaraki, Arwa, McArthur, Grant A., Sheppard, Karen E., Smith, Lorey K.
Publicado 2021

PRMT5: An Emerging Target for Pancreatic Adenocarcinoma

por Lee, Michael K. C., Grimmond, Sean M., McArthur, Grant A., Sheppard, Karen E.
Publicado 2021

Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?

por Smith, Lorey K., Arabi, Shaghayegh, Lelliott, Emily J., McArthur, Grant A., Sheppard, Karen E.
Publicado 2020

The therapeutic potential of targeting minimal residual disease in melanoma

por Patel, Riyaben P, Somasundram, Pretashini M, Smith, Lorey K., Sheppard, Karen E., McArthur, Grant A.
Publicado 2023

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway

por Santiappillai, Nancy T., Abuhammad, Shatha, Slater, Alison, Kirby, Laura, McArthur, Grant A., Sheppard, Karen E., Smith, Lorey K.
Publicado 2021

PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing in melanoma

por Chan, Lok Hang, Wang, Peihan, Abuhammad, Shatha, Lim, Lydia Rui Jia, Cursons, Joseph, Sheppard, Karen E., Goode, David L.
Publicado 2023

Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours

por Wong, Stephen Q., Li, Jason, Salemi, Renato, Sheppard, Karen E., Hongdo Do, Tothill, Richard W., McArthur, Grant A., Dobrovic, Alexander
Publicado 2013

Genome-wide RNAi screen for genes regulating glycolytic response to vemurafenib in BRAF(V600) melanoma cells

por Smith, Lorey K., Parmenter, Tiffany, Gould, Cathryn M., Madhamshettiwar, Piyush B., Sheppard, Karen E., Simpson, Kaylene J., McArthur, Grant A.
Publicado 2020

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461

por Son, Jinbae, Hannan, Katherine M., Poortinga, Gretchen, Hein, Nadine, Cameron, Donald P., Ganley, Austen R. D., Sheppard, Karen E., Pearson, Richard B., Hannan, Ross D., Sanij, Elaine
Publicado 2020

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma

por Wong, Stephen Q., Behren, Andreas, Mar, Victoria J., Woods, Katherine, Li, Jason, Martin, Claire, Sheppard, Karen E., Wolfe, Rory, Kelly, John, Cebon, Jonathan, Dobrovic, Alexander, McArthur, Grant A.
Publicado 2014

Enhancing Adoptive Cell Transfer with Combination BRAF-MEK and CDK4/6 Inhibitors in Melanoma

por Lau, Peter Kar Han, Cullinane, Carleen, Jackson, Susan, Walker, Rachael, Smith, Lorey K., Slater, Alison, Kirby, Laura, Patel, Riyaben P., von Scheidt, Bianca, Slaney, Clare Y., McArthur, Grant A., Sheppard, Karen E.
Publicado 2021

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-gra...

por Yan, Shunfei, Xuan, Jiachen, Brajanovski, Natalie, Tancock, Madeleine R. C., Madhamshettiwar, Piyush B., Simpson, Kaylene J., Ellis, Sarah, Kang, Jian, Cullinane, Carleen, Sheppard, Karen E., Hannan, Katherine M., Hannan, Ross D., Sanij, Elaine, Pearson, Richard B., Chan, Keefe T.
Publicado 2020

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

por Tan, Lih Yin, Mintoff, Chris, Johan, M. Zahied, Ebert, Brenton W., Fedele, Clare, Zhang, You Fang, Szeto, Pacman, Sheppard, Karen E., McArthur, Grant A., Foster-Smith, Erwin, Ruszkiewicz, Andrew, Brown, Michael P., Bonder, Claudine S., Shackleton, Mark, Ebert, Lisa M.
Publicado 2016

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy

por Lelliott, Emily J., Cullinane, Carleen, Martin, Claire A., Walker, Rachael, Ramsbottom, Kelly M., Souza-Fonseca-Guimaraes, Fernando, Abuhammad, Shatha, Michie, Jessica, Kirby, Laura, Young, Richard J., Slater, Alison, Lau, Peter, Meeth, Katrina, Oliaro, Jane, Haynes, Nicole, McArthur, Grant A., Sheppard, Karen E.
Publicado 2019

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

por Quin, Jaclyn, Chan, Keefe T., Devlin, Jennifer R., Cameron, Donald P., Diesch, Jeannine, Cullinane, Carleen, Ahern, Jessica, Khot, Amit, Hein, Nadine, George, Amee J., Hannan, Katherine M, Poortinga, Gretchen, Sheppard, Karen E., Khanna, Kum Kum, Johnstone, Ricky W., Drygin, Denis, McArthur, Grant A., Pearson, Richard B., Sanij, Elaine, Hannan, Ross D.
Publicado 2016

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

por Lau, Peter Kar Han, Feran, Breon, Smith, Lorey, Lasocki, Arian, Molania, Ramyar, Smith, Kortnye, Weppler, Alison, Angel, Christopher, Kee, Damien, Bhave, Prachi, Lee, Belinda, Young, Richard J, Iravani, Amir, Yeang, Hanxian Aw, Vergara, Ismael A, Kok, David, Drummond, Kate, Neeson, Paul Joseph, Sheppard, Karen E, Papenfuss, Tony, Solomon, Benjamin J, Sandhu, Shahneen, McArthur, Grant A
Publicado 2021